"We are delighted by the positive response to VagiVital Active Glide. The strong sales demonstrate that we have developed a product that truly meets our customers' needs and preferences," says Anna Linton, CEO of Peptonic. "This is a fantastic start and provides a solid foundation for the next step: launching the product in the U.S. following regulatory approval."

VagiVital Active Glide is a fragrance-free, water-based lubricant designed to enhance intimate moments while providing deep hydration without irritation. The product is based on Peptonic's clinically proven gel base, AktivGel, known for its moisturizing and soothing properties. In its initial weeks, sales have been conducted through the Company's own webshops, and the product will in February also be available in pharmacy e-stores, further improving accessibility for customers.

The global market for personal lubricants was valued at approximately SEK 13 billion in 2024 and is expected to continue its strong growth. Raising awareness of sexual health, increasing demand for products that enhance intimacy, and greater acceptance of lubricant use are driving this growth. Women represent a particularly important target group, as lubricants are increasingly used both to enhance intimate experiences and for hydration and care.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                                                                                      
Email: anna.linton@peptonicmedical.se                                                                                                                    
Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                         
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.